Literature DB >> 15970496

Non-alcoholic fatty liver disease (NAFLD) in children.

Eve A Roberts1.   

Abstract

Childhood NAFLD has become an important childhood liver disease, and it is probably highly prevalent. The full of spectrum of NAFLD has been identified in children. It is not currently known whether or not simple hepatic steatosis in children is benign or whether it evolves to NASH over time. In contrast, childhood NASH certainly can have serious consequences. Cirrhosis is apparently rare in children with NAFLD, but it definitely occurs. Childhood NAFLD may occur in very young children, and there is no female predominance in the pediatric age bracket. Children present with vague abdominal pain, if they have any symptoms at all, but frequently hepatic steatosis is found incidentally on abdominal imaging. Laboratory studies show that serum aminotransferase abnormalities are rather moderate, with serum alanine aminotransferase (ALT) more elevated than serum aspartate aminotransferase (AST). Hypertriglyceridemia is the typical blood lipid abnormality, although hypercholesterolemia may occur. NASH may be more severe in children from certain ethnic groups, including Hispanics and Asians, or in association with certain metabolic disorders characterized by abnormalities in insulin receptor structure or signaling, such as lipodystrophy syndromes. Weight loss through dietary redesign and a regimen of regular exercise remains the mainstay for treatment for childhood NAFLD. A dietary strategy to minimize postprandial hyperinsulinemia and overall fat intake, such as a low glycemic index diet, may be the best dietary strategy. The real efficacy of drug treatments in children requires further investigation. The overriding message is that childhood obesity poses important health problems, including but not limited to potentially severe chronic liver disease. Early diagnosis of children who are only overweight is a worthy goal so that strategies to limit obesity can be instituted as early as possible. Identification of genetic risks is important, but management will invariably require changes in environmental factors. In addition to individual treatment, a multifaceted, societal initiative is required for solving the childhood obesity epidemic.

Entities:  

Mesh:

Year:  2005        PMID: 15970496     DOI: 10.2741/1699

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  11 in total

1.  Nonalcoholic fatty liver disease.

Authors:  Diana Mager; Eve Roberts
Journal:  CMAJ       Date:  2005-09-27       Impact factor: 8.262

2.  Congenital and environmental factors associated with adipocyte dysregulation as defects of insulin resistance.

Authors:  Chao-Ping Wang; Fu-Mei Chung; Shyi-Jang Shin; Yau-Jiunn Lee
Journal:  Rev Diabet Stud       Date:  2007-08-10

Review 3.  Fatty liver in childhood.

Authors:  Yesim Ozturk; Ozlem Bekem Soylu
Journal:  World J Hepatol       Date:  2014-01-27

4.  Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention.

Authors:  Valerio Nobili; Anna Alisi; Massimiliano Raponi
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

5.  Organ-specific roles of CYP1A1 during detoxication of dietary benzo[a]pyrene.

Authors:  Zhanquan Shi; Nadine Dragin; Marina Gálvez-Peralta; Lucia F Jorge-Nebert; Marian L Miller; Bin Wang; Daniel W Nebert
Journal:  Mol Pharmacol       Date:  2010-04-06       Impact factor: 4.436

6.  Metabolic syndrome in overweight children from the city of Botucatu - São Paulo State - Brazil: agreement among six diagnostic criteria.

Authors:  Ana Elisa M Rinaldi; Gustavo D Pimentel; Avany F Pereira; Gleice Fcp Gabriel; Fernando Moreto; Roberto C Burini
Journal:  Diabetol Metab Syndr       Date:  2010-06-09       Impact factor: 3.320

7.  Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents.

Authors:  Roya Kelishadi; Stephen R Cook; Atoosa Adibi; Zahra Faghihimani; Shohreh Ghatrehsamani; Abolfazl Beihaghi; Hamidreza Salehi; Noushin Khavarian; Parinaz Poursafa
Journal:  Diabetol Metab Syndr       Date:  2009-12-22       Impact factor: 3.320

Review 8.  Advances in pediatric nonalcoholic fatty liver disease.

Authors:  Rohit Loomba; Claude B Sirlin; Jeffrey B Schwimmer; Joel E Lavine
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

Review 9.  Advanced MRI methods for assessment of chronic liver disease.

Authors:  Bachir Taouli; Richard L Ehman; Scott B Reeder
Journal:  AJR Am J Roentgenol       Date:  2009-07       Impact factor: 3.959

Review 10.  Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets.

Authors:  Valentina Giorgio; Federica Prono; Francesca Graziano; Valerio Nobili
Journal:  BMC Pediatr       Date:  2013-03-25       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.